AbbVie secures tariff relief in drug pricing deal, pledges $100B investment
Seeking Alpha News (Mon, 12-Jan 11:00 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 12-Jan 10:50 PM ET)
Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
TipRanks (Thu, 8-Jan 11:31 AM ET)
AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
PRNewswire (Wed, 7-Jan 4:01 PM ET)
Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
Benzinga (Wed, 7-Jan 1:45 PM ET)
Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
TipRanks (Wed, 7-Jan 11:33 AM ET)
Amgen (AMGN) Receives a Buy from Piper Sandler
TipRanks (Wed, 7-Jan 7:27 AM ET)
Citi Sticks to Their Hold Rating for Amgen (AMGN)
TipRanks (Wed, 7-Jan 6:47 AM ET)
Dark Blue Therapeutics acquired by Amgen for up to $840 million
PRNewswire (Tue, 6-Jan 9:29 AM ET)
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
PRNewswire (Tue, 6-Jan 9:01 AM ET)
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen trades on the NASDAQ stock market under the symbol AMGN.
As of January 12, 2026, AMGN stock price declined to $325.54 with 1,811,090 million shares trading.
AMGN has a beta of 0.27, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.04 to the broad based SPY ETF.
AMGN has a market cap of $175.26 billion. This is considered a Large Cap stock.
Last quarter Amgen reported $10 billion in Revenue and $5.64 earnings per share. This beat revenue expectation by $601 million and exceeded earnings estimates by $.63.
In the last 3 years, AMGN traded as high as $346.85 and as low as $211.71.
The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, IVV.
AMGN has outperformed the market in the last year with a return of +26.8%, while the SPY ETF gained +19.2%. In the last 3 month period, AMGN beat the market returning +11.0%, while SPY returned +3.9%. However, in the most recent 2 weeks AMGN has underperformed the stock market by returning -2.2%, while SPY returned +0.7%.
AMGN support price is $321.28 and resistance is $330.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.